{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:00:55Z","timestamp":1794024055056,"version":"4.8.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["GR-2021-12373041"],"award-info":[{"award-number":["GR-2021-12373041"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"crossref","award":["GR-2013-02-355322"],"award-info":[{"award-number":["GR-2013-02-355322"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Ministry of University and Research","award":["project MNESYS (PE0000006)"],"award-info":[{"award-number":["project MNESYS (PE0000006)"]}]},{"name":"Merck Serono S.p.A, Rome, Italy","award":["MS700568_0091"],"award-info":[{"award-number":["MS700568_0091"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"DOI":"10.1186\/s12974-026-03725-2","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T06:54:35Z","timestamp":1770879275000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of cladribine tablets on intrathecal inflammation in relapsing-remitting multiple sclerosis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0358-9431","authenticated-orcid":false,"given":"Damiano","family":"Marastoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Eccher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6289-9144","authenticated-orcid":false,"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Anni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Crescenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Virla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Sicchieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermanna","family":"Turano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Tamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Camera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ziccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Zanetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Benedetta","family":"Pizzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fratucello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Bonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pia","family":"Sormani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3362-7403","authenticated-orcid":false,"given":"Massimiliano","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"issue":"9","key":"3725_CR1","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","volume":"77","author":"L Kappos","year":"2020","unstructured":"Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent progression vs Relapse-Associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol. 2020;77(9):1132\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1568.","journal-title":"JAMA Neurol"},{"issue":"9","key":"3725_CR2","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H, et al. How patients with multiple sclerosis acquire disability. Brain. 2022;145(9):3147\u201361. https:\/\/doi.org\/10.1093\/brain\/awac016.","journal-title":"Brain"},{"key":"3725_CR3","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","volume":"9","author":"H Lassmann","year":"2018","unstructured":"Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2018;9:3116. https:\/\/doi.org\/10.3389\/fimmu.2018.03116.","journal-title":"Front Immunol"},{"issue":"Pt 9","key":"3725_CR4","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain. 2011;134(Pt 9):2755\u201371. https:\/\/doi.org\/10.1093\/brain\/awr182.","journal-title":"Brain"},{"issue":"4","key":"3725_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.25197","volume":"83","author":"R Magliozzi","year":"2018","unstructured":"Magliozzi R, Howell OW, Nicholas R, et al. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol. 2018;83(4):739\u201355. https:\/\/doi.org\/10.1002\/ana.25197.","journal-title":"Ann Neurol"},{"issue":"3","key":"3725_CR6","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/ana.25786","volume":"88","author":"R Magliozzi","year":"2020","unstructured":"Magliozzi R, Scalfari A, Pisani AI, et al. The CSF profile linked to cortical damage predicts multiple sclerosis activity. Ann Neurol. 2020;88(3):562\u201373. https:\/\/doi.org\/10.1002\/ana.25786.","journal-title":"Ann Neurol"},{"issue":"7","key":"3725_CR7","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3174\/ajnr.A5660","volume":"39","author":"M Absinta","year":"2018","unstructured":"Absinta M, Sati P, Fechner A, Schindler MK, Nair G, Reich DS. Identification of chronic active multiple sclerosis lesions on 3T MRI. AJNR Am J Neuroradiol. 2018;39(7):1233\u20138. https:\/\/doi.org\/10.3174\/ajnr.A5660.","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"3725_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ana.26913","volume":"96","author":"M Calabrese","year":"2024","unstructured":"Calabrese M, Preziosa P, Scalfari A, et al. Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol. 2024;96(1):1\u201320. https:\/\/doi.org\/10.1002\/ana.26913.","journal-title":"Ann Neurol"},{"issue":"1","key":"3725_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13073-022-01097-9","volume":"14","author":"M Heming","year":"2022","unstructured":"Heming M, Borsch AL, Wiendl H, Meyer Zu Horste G. High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses. Genome Med. 2022;14(1):94. https:\/\/doi.org\/10.1186\/s13073-022-01097-9.","journal-title":"Genome Med"},{"key":"3725_CR10","doi-asserted-by":"publisher","unstructured":"Marastoni D, Magliozzi R, Bolzan A, et al. CSF levels of CXCL12 and osteopontin as early markers of primary progressive multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021;8(6). https:\/\/doi.org\/10.1212\/nxi.0000000000001083.","DOI":"10.1212\/nxi.0000000000001083"},{"key":"3725_CR11","doi-asserted-by":"publisher","first-page":"1343892","DOI":"10.3389\/fimmu.2024.1343892","volume":"15","author":"D Marastoni","year":"2024","unstructured":"Marastoni D, Foschi M, Eccher C, et al. CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis. Front Immunol. 2024;15:1343892. https:\/\/doi.org\/10.3389\/fimmu.2024.1343892.","journal-title":"Front Immunol"},{"key":"3725_CR12","doi-asserted-by":"publisher","unstructured":"Pinteac R, Montalban X, Comabella M. Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. Neurol Neuroimmunol Neuroinflamm. 2021;8(1). https:\/\/doi.org\/10.1212\/nxi.0000000000000921.","DOI":"10.1212\/nxi.0000000000000921"},{"issue":"6","key":"3725_CR13","doi-asserted-by":"publisher","first-page":"e98588","DOI":"10.1371\/journal.pone.0098588","volume":"9","author":"M Stilund","year":"2014","unstructured":"Stilund M, Reuschlein AK, Christensen T, M\u00f8ller HJ, Rasmussen PV, Petersen T. Soluble CD163 as a marker of macrophage activity in newly diagnosed patients with multiple sclerosis. PLoS ONE. 2014;9(6):e98588. https:\/\/doi.org\/10.1371\/journal.pone.0098588.","journal-title":"PLoS ONE"},{"issue":"5","key":"3725_CR14","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00401-023-02627-4","volume":"146","author":"A Hofmann","year":"2023","unstructured":"Hofmann A, Krajnc N, Dal-Bianco A, et al. Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosis. Acta Neuropathol. 2023;146(5):707\u201324. https:\/\/doi.org\/10.1007\/s00401-023-02627-4.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"3725_CR15","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1177\/1352458509355068","volume":"16","author":"J Mellergard","year":"2010","unstructured":"Mellergard J, Edstrom M, Vrethem M, Ernerudh J, Dahle C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler. 2010;16(2):208\u201317. https:\/\/doi.org\/10.1177\/1352458509355068.","journal-title":"Mult Scler"},{"key":"3725_CR16","doi-asserted-by":"publisher","first-page":"577756","DOI":"10.1016\/j.jneuroim.2021.577756","volume":"361","author":"J Talbot","year":"2021","unstructured":"Talbot J, Hojsgaard Chow H, Holm Hansen R, von Essen MR, Sellebjerg F. Immunological effects of dimethyl fumarate treatment in blood and CSF of patients with primary progressive MS. J Neuroimmunol. 2021;361:577756. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577756.","journal-title":"J Neuroimmunol"},{"issue":"4","key":"3725_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1001\/jamaneurol.2024.0017","volume":"81","author":"AH Cross","year":"2024","unstructured":"Cross AH, Gelfand JM, Thebault S, et al. Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis. JAMA Neurol. 2024;81(4):373\u201383. https:\/\/doi.org\/10.1001\/jamaneurol.2024.0017.","journal-title":"JAMA Neurol"},{"issue":"2","key":"3725_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.2165\/00003088-199732020-00003","volume":"32","author":"J Liliemark","year":"1997","unstructured":"Liliemark J. The clinical pharmacokinetics of cladribine. Clin Pharmacokinet. 1997;32(2):120\u201331. https:\/\/doi.org\/10.2165\/00003088-199732020-00003.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"3725_CR19","first-page":"1235","volume":"54","author":"CM Kearns","year":"1994","unstructured":"Kearns CM, Blakley RL, Santana VM, Crom WR. Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia. Cancer Res. 1994;54(5):1235\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"3725_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"issue":"11","key":"3725_CR21","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","volume":"80","author":"J Muller","year":"2023","unstructured":"Muller J, Cagol A, Lorscheider J, et al. Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: A systematic review. JAMA Neurol. 2023;80(11):1232\u201345. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3331.","journal-title":"JAMA Neurol"},{"issue":"22","key":"3725_CR22","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73(22):1914\u201322. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c47cc2.","journal-title":"Neurology"},{"issue":"5","key":"3725_CR23","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1212\/WNL.0b013e31820a0cc4","volume":"76","author":"JJ Geurts","year":"2011","unstructured":"Geurts JJ, Roosendaal SD, Calabrese M, et al. Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. Neurology. 2011;76(5):418\u201324. https:\/\/doi.org\/10.1212\/WNL.0b013e31820a0cc4.","journal-title":"Neurology"},{"key":"3725_CR24","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1109\/EMBC.2016.7591443","volume":"2016","author":"PA Yushkevich","year":"2016","unstructured":"Yushkevich PA, Yang G, Gerig G. ITK-SNAP: an interactive tool for semi-automatic segmentation of multi-modality biomedical images. Annu Int Conf IEEE Eng Med Biol Soc. 2016;2016:3342\u20135. https:\/\/doi.org\/10.1109\/EMBC.2016.7591443.","journal-title":"Annu Int Conf IEEE Eng Med Biol Soc"},{"issue":"11","key":"3725_CR25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1177\/1352458514525868","volume":"20","author":"P Sati","year":"2014","unstructured":"Sati P, Thomasson DM, Li N, et al. Rapid, high-resolution, whole-brain, susceptibility-based MRI of multiple sclerosis. Mult Scler. 2014;20(11):1464\u201370. https:\/\/doi.org\/10.1177\/1352458514525868.","journal-title":"Mult Scler"},{"issue":"6","key":"3725_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1177\/1352458506070933","volume":"12","author":"MP Amato","year":"2006","unstructured":"Amato MP, Portaccio E, Goretti B, et al. The rao\u2019s brief repeatable battery and Stroop test: normative values with age, education and gender corrections in an Italian population. Mult Scler. 2006;12(6):787\u201393. https:\/\/doi.org\/10.1177\/1352458506070933.","journal-title":"Mult Scler"},{"key":"3725_CR27","first-page":"111","volume":"07\/01","author":"P Caffarra","year":"2002","unstructured":"Caffarra P, Vezzadini G, Francesca D, Zonato F, Venneri A. A short version of the Stroop test: normative data in an Italian population sample. Nuova Rivista Di Neurologia. 2002;07\/01:12:111\u20135.","journal-title":"Nuova Rivista Di Neurologia"},{"issue":"3","key":"3725_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s10072-013-1520-8","volume":"35","author":"A Costa","year":"2014","unstructured":"Costa A, Bagoj E, Monaco M, et al. Standardization and normative data obtained in the Italian population for a new verbal fluency instrument, the phonemic\/semantic alternate fluency test. Neurol Sci. 2014;35(3):365\u201372. https:\/\/doi.org\/10.1007\/s10072-013-1520-8.","journal-title":"Neurol Sci"},{"issue":"4","key":"3725_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-011-0489-4","volume":"32","author":"R Cattelani","year":"2011","unstructured":"Cattelani R, Dal Sasso F, Corsini D, Posteraro L. The modified Five-Point test: normative data for a sample of Italian healthy adults aged 16\u201360. Neurol Sci. 2011;32(4):595\u2013601. https:\/\/doi.org\/10.1007\/s10072-011-0489-4.","journal-title":"Neurol Sci"},{"issue":"5","key":"3725_CR30","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1111\/ene.15697","volume":"30","author":"S Ziccardi","year":"2023","unstructured":"Ziccardi S, Pisani AI, Schiavi GM, et al. Cortical lesions at diagnosis predict long-term cognitive impairment in multiple sclerosis: A 20-year study. Eur J Neurol. 2023;30(5):1378\u201388. https:\/\/doi.org\/10.1111\/ene.15697.","journal-title":"Eur J Neurol"},{"key":"3725_CR31","doi-asserted-by":"publisher","unstructured":"Ziccardi S, Fuchs TA, Guandalini M, Marastoni D, Benedict RH, Calabrese M. Cognitive progression independent of relapse and MRI activity in multiple sclerosis. Neurol Open Access. 2025;1(e0011). https:\/\/doi.org\/10.1212\/WN9.0000000000000005.","DOI":"10.1212\/WN9.0000000000000005"},{"issue":"10","key":"3725_CR32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2017.119","volume":"13","author":"H Wiendl","year":"2017","unstructured":"Wiendl H. Cladribine - an old newcomer for pulsed immune reconstitution in MS. Nat Rev Neurol. 2017;13(10):573\u20134. https:\/\/doi.org\/10.1038\/nrneurol.2017.119.","journal-title":"Nat Rev Neurol"},{"key":"3725_CR33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.msard.2019.02.018","volume":"30","author":"D Baker","year":"2019","unstructured":"Baker D, Pryce G, Herrod SS, Schmierer K. Potential mechanisms of action related to the efficacy and safety of cladribine. Mult Scler Relat Disord. 2019;30:176\u201386. https:\/\/doi.org\/10.1016\/j.msard.2019.02.018.","journal-title":"Mult Scler Relat Disord"},{"key":"3725_CR34","doi-asserted-by":"publisher","unstructured":"Fresegna D, Bullitta S, Musella A, et al. Re-Examining the role of TNF in MS pathogenesis and therapy. Cells. 2020;9(10). https:\/\/doi.org\/10.3390\/cells9102290.","DOI":"10.3390\/cells9102290"},{"key":"3725_CR35","doi-asserted-by":"publisher","unstructured":"Magliozzi R, Pezzini F, Pucci M, et al. Changes in cerebrospinal fluid balance of TNF and TNF receptors in Naive multiple sclerosis patients: early involvement in compartmentalised intrathecal inflammation. Cells. 2021;10(7). https:\/\/doi.org\/10.3390\/cells10071712.","DOI":"10.3390\/cells10071712"},{"issue":"1","key":"3725_CR36","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40478-020-00938-1","volume":"8","author":"RE James","year":"2020","unstructured":"James RE, Schalks R, Browne E, et al. Persistent elevation of intrathecal pro-inflammatory cytokines leads to multiple sclerosis-like cortical demyelination and neurodegeneration. Acta Neuropathol Commun. 2020;8(1):66. https:\/\/doi.org\/10.1186\/s40478-020-00938-1.","journal-title":"Acta Neuropathol Commun"},{"key":"3725_CR37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.msard.2018.10.006","volume":"27","author":"K Rejdak","year":"2019","unstructured":"Rejdak K, Stelmasiak Z, Grieb P. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study. Mult Scler Relat Disord. 2019;27:117\u201320. https:\/\/doi.org\/10.1016\/j.msard.2018.10.006.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"3725_CR38","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/WNF.0b013e318204cd90","volume":"34","author":"TP Leist","year":"2011","unstructured":"Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011;34(1):28\u201335. https:\/\/doi.org\/10.1097\/WNF.0b013e318204cd90.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"3725_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/cei.13473","volume":"201","author":"LO Jorgensen","year":"2020","unstructured":"Jorgensen LO, Hyrlov KH, Elkjaer ML, et al. Cladribine modifies functional properties of microglia. Clin Exp Immunol. 2020;201(3):328\u201340. https:\/\/doi.org\/10.1111\/cei.13473.","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"3725_CR40","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s11481-012-9387-7","volume":"7","author":"V Singh","year":"2012","unstructured":"Singh V, Voss EV, Benardais K, Stangel M. Effects of 2-chlorodeoxyadenosine (Cladribine) on primary rat microglia. J Neuroimmune Pharmacol. 2012;7(4):939\u201350. https:\/\/doi.org\/10.1007\/s11481-012-9387-7.","journal-title":"J Neuroimmune Pharmacol"},{"key":"3725_CR41","doi-asserted-by":"publisher","first-page":"108571","DOI":"10.1016\/j.intimp.2022.108571","volume":"105","author":"F Aybar","year":"2022","unstructured":"Aybar F, Julia Perez M, Silvina Marcora M, et al. 2-Chlorodeoxyadenosine (Cladribine) preferentially inhibits the biological activity of microglial cells. Int Immunopharmacol. 2022;105:108571. https:\/\/doi.org\/10.1016\/j.intimp.2022.108571.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"3725_CR42","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12974-022-02588-7","volume":"19","author":"CB Schroeter","year":"2022","unstructured":"Schroeter CB, Rolfes L, Gothan KSS, et al. Cladribine treatment improves cortical network functionality in a mouse model of autoimmune encephalomyelitis. J Neuroinflammation. 2022;19(1):270. https:\/\/doi.org\/10.1186\/s12974-022-02588-7.","journal-title":"J Neuroinflammation"},{"issue":"1\u20132","key":"3725_CR43","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2013.08.009","volume":"264","author":"A Musella","year":"2013","unstructured":"Musella A, Mandolesi G, Gentile A, et al. Cladribine interferes with IL-1beta synaptic effects in experimental multiple sclerosis. J Neuroimmunol. 2013;264(1\u20132):8\u201313. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.08.009.","journal-title":"J Neuroimmunol"},{"issue":"6","key":"3725_CR44","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/archneurol.2010.99","volume":"67","author":"L Piccio","year":"2010","unstructured":"Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol. 2010;67(6):707\u201314. https:\/\/doi.org\/10.1001\/archneurol.2010.99.","journal-title":"Arch Neurol"},{"key":"3725_CR45","doi-asserted-by":"publisher","first-page":"205521731562380","DOI":"10.1177\/2055217315623800","volume":"1","author":"E Alvarez","year":"2015","unstructured":"Alvarez E, Piccio L, Mikesell RJ, et al. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures. Mult Scler J Exp Transl Clin. 2015;1:2055217315623800. https:\/\/doi.org\/10.1177\/2055217315623800.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"1","key":"3725_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1352458513490544","volume":"20","author":"M Axelsson","year":"2014","unstructured":"Axelsson M, Malmestr\u00f6m C, Gunnarsson M, et al. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler. 2014;20(1):43\u201350. https:\/\/doi.org\/10.1177\/1352458513490544.","journal-title":"Mult Scler"},{"issue":"1","key":"3725_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/1352458516639384","volume":"23","author":"L Novakova","year":"2017","unstructured":"Novakova L, Axelsson M, Khademi M, et al. Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of Fingolimod efficacy in multiple sclerosis. Mult Scler. 2017;23(1):62\u201371. https:\/\/doi.org\/10.1177\/1352458516639384.","journal-title":"Mult Scler"},{"key":"3725_CR48","doi-asserted-by":"publisher","first-page":"175628642513517","DOI":"10.1177\/17562864251351760","volume":"18","author":"K Schmierer","year":"2025","unstructured":"Schmierer K, Wiendl H, Barkhof F, et al. Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study. Ther Adv Neurol Disord. 2025;18:17562864251351760. https:\/\/doi.org\/10.1177\/17562864251351760.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"3725_CR49","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1093\/brain\/awab033","volume":"144","author":"L Haider","year":"2021","unstructured":"Haider L, Prados F, Chung K, et al. Cortical involvement determines impairment 30 years after a clinically isolated syndrome. Brain. 2021;144(5):1384\u201395. https:\/\/doi.org\/10.1093\/brain\/awab033.","journal-title":"Brain"},{"issue":"14","key":"3725_CR50","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1212\/WNL.0b013e3181f5d4da","volume":"75","author":"M Calabrese","year":"2010","unstructured":"Calabrese M, Battaglini M, Giorgio A, et al. Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis. Neurology. 2010;75(14):1234\u201340. https:\/\/doi.org\/10.1212\/WNL.0b013e3181f5d4da.","journal-title":"Neurology"},{"issue":"8","key":"3725_CR51","doi-asserted-by":"publisher","first-page":"e0135428","DOI":"10.1371\/journal.pone.0135428","volume":"10","author":"M Calabrese","year":"2015","unstructured":"Calabrese M, Reynolds R, Magliozzi R, et al. Regional distribution and evolution of Gray matter damage in different populations of multiple sclerosis patients. PLoS ONE. 2015;10(8):e0135428. https:\/\/doi.org\/10.1371\/journal.pone.0135428.","journal-title":"PLoS ONE"},{"issue":"24","key":"3725_CR52","doi-asserted-by":"publisher","first-page":"e2107","DOI":"10.1212\/WNL.0000000000005685","volume":"90","author":"A Scalfari","year":"2018","unstructured":"Scalfari A, Romualdi C, Nicholas RS, et al. The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis. Neurology. 2018;90(24):e2107\u201318. https:\/\/doi.org\/10.1212\/WNL.0000000000005685.","journal-title":"Neurology"},{"issue":"2","key":"3725_CR53","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1177\/1352458517690269","volume":"24","author":"N De Stefano","year":"2018","unstructured":"De Stefano N, Giorgio A, Battaglini M, et al. Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. Mult Scler. 2018;24(2):222\u20136. https:\/\/doi.org\/10.1177\/1352458517690269.","journal-title":"Mult Scler"},{"issue":"1","key":"3725_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/ene.15579","volume":"30","author":"R Cortese","year":"2023","unstructured":"Cortese R, Battaglini M, Sormani MP, et al. Reduction in grey matter atrophy in patients with relapsing multiple sclerosis following treatment with cladribine tablets. Eur J Neurol. 2023;30(1):179\u201386. https:\/\/doi.org\/10.1111\/ene.15579.","journal-title":"Eur J Neurol"},{"key":"3725_CR55","doi-asserted-by":"publisher","first-page":"110304","DOI":"10.1016\/j.clim.2024.110304","volume":"265","author":"M Monif","year":"2024","unstructured":"Monif M, Sequeira RP, Muscat A, et al. CLADIN- cladribine and innate immune response in multiple sclerosis - A phase IV prospective study. Clin Immunol. 2024;265:110304. https:\/\/doi.org\/10.1016\/j.clim.2024.110304.","journal-title":"Clin Immunol"},{"key":"3725_CR56","doi-asserted-by":"publisher","first-page":"1571978","DOI":"10.3389\/fimmu.2025.1571978","volume":"16","author":"H Wiendl","year":"2025","unstructured":"Wiendl H, Barkhof F, Montalban X, et al. Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study. Front Immunol. 2025;16:1571978. https:\/\/doi.org\/10.3389\/fimmu.2025.1571978.","journal-title":"Front Immunol"},{"issue":"4","key":"3725_CR57","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.3390\/ijms24043768","volume":"24","author":"F Pezzini","year":"2023","unstructured":"Pezzini F, Pisani A, Mazziotti V, et al. Intrathecal versus peripheral inflammatory protein profile in MS patients at diagnosis: A comprehensive investigation on serum and CSF. Int J Mol Sci. 2023;24(4):3768. https:\/\/doi.org\/10.3390\/ijms24043768.","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-026-03725-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-026-03725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-026-03725-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T11:38:34Z","timestamp":1773833914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12974-026-03725-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3725"],"URL":"https:\/\/doi.org\/10.1186\/s12974-026-03725-2","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"assertion":[{"value":"2 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local ethics committee (Comitato etico per la sperimentazione clinica delle province di Verona e Rovigo) approved the study (CLAD19 Study, 2179CESC), and written informed consent was obtained from all the patients. Clinical trials registration: EudraCT Number: 2018-004947-21.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"DM received honoraria for research or speaking and funds for travel from Biogen Idec, Roche, Sanofi-Genzyme, Novartis, and Merck-Serono. VC received research grant from European Charcot Foundation, received support for scientific meetings from Biogen, Janssen, Novartis, BMS, Roche and speaking honoraria from Novartis. MPS received consulting fees from Biogen, Merck, Novartis, Sanofi, Roche, Immunic, Alexion, Bristol-Meyer Squibb. MC received speaker honoraria from Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, and Roche and received research support from the Progressive MS Alliance, Italian Minister of Health, the Novartis Pharma, Roche, Bristol Myers Squibb and Merck Serono.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}